NovoCure (NVCR) Total Current Liabilities (2014 - 2026)

NovoCure (NVCR) has reported Total Current Liabilities for 13 consecutive years, with $220.7 million the latest figure, recorded in Q2 2026.

• Quarterly Total Current Liabilities fell 70.56% year-over-year to $220.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $220.7 million (down 70.56% YoY) and the FY2025 annual result came in at $223.2 million, down 70.49% from the prior year.
• Total Current Liabilities grew to $220.7 million in Q2 2026 per NVCR's latest filing, from $217.6 million in the prior quarter.
• Over the last five years, Total Current Liabilities for NVCR reached as high as $776.0 million in Q3 2025 and fell as low as $127.8 million in Q1 2022.
• A 5-year average of $330.5 million and a median of $174.1 million in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Current Liabilities jumped 367.67% — and 2026, when it plunged 70.73%.
• Year by year, Total Current Liabilities stood at $158.8 million in 2022, then rose by 12.81% to $179.1 million in 2023, then soared by 322.3% to $756.4 million in 2024, then plunged by 70.49% to $223.2 million in 2025, then slipped by 1.13% to $220.7 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $220.7 million, $217.6 million, and $223.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.